Century Therapeutics, Inc. (IPSC)
Automate Your Wheel Strategy on IPSC
With Tiblio's Option Bot, you can configure your own wheel strategy including IPSC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IPSC
- Rev/Share 1.3357
- Book/Share 2.7951
- PB 0.1898
- Debt/Equity 0.1988
- CurrentRatio 11.6963
- ROIC -0.1181
- MktCap 45698628.0
- FreeCF/Share -1.3267
- PFCF -0.4004
- PE -2.079
- Debt/Assets 0.1514
- DivYield 0
- ROE -0.1071
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a year ago.
Read More
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Century Therapeutics (IPSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Century Therapeutics, Inc. (IPSC)
- IPO Date 2021-06-18
- Website https://www.centurytx.com
- Industry Biotechnology
- CEO Dr. Brent Pfeiffenberger M.B.A., Pharm.D.
- Employees 140